This was the stock's second consecutive day of losses.

The overhaul was nicknamed Project Arden as a nod to the Elizabeth Arden beauty salon, best known at the time for its ...

An estimated 20 million people are diagnosed annually with cancer, while cancer kills almost 10 million people a year ...

An engineered protein turns off the kind of immune cells most likely to damage tissue as part of Type-1 diabetes, hepatitis, ...

A lawsuit against genomics firm 23andMe is stirring a debate about what the proper role of government is in regulating how private companies use sensitive data. In June, 27 states filed a lawsuit ...

San Francisco-based 23andMe filed for Chapter 11 bankruptcy protection in the Eastern Missouri federal court district in ...

-Regeneron Pharmaceuticals has declined to submit a new bid for genetic testing company 23andMe exceeding its original winning bid of $256 million, a company spokesperson told Reuters on Monday ...

After a seven-day trial, jurors sided with Regeneron on 10 of 11 claims, and awarded $135.6 million in compensatory damages—the top end of what Regeneron’s expert suggested—and another $271. ...

Regeneron announced the purchase Monday. In March, 23andMe initiated voluntary Chapter 11 proceedings in the U.S. Bankruptcy Court to be sold. 23andMe offers DNA testing with an ancestry breakdown ...

Regeneron Pharmaceuticals agreed to purchase 23andMe for $256 million in a bankruptcy court auction, the company said Monday. The move allows 23andMe to continue to provide DNA testing services.

Regeneron, a biotech company, will acquire 23andMe for $256 million and vowed to comply with the genetic testing company's privacy policies.